India's CDMO market set to double by 2028 amid Asia's healthcare boom

ANI February 9, 2025 340 views

India's Contract Development and Manufacturing Organization (CDMO) market is experiencing unprecedented growth, expected to double from $7 billion to $14 billion by 2028. The surge is driven by cost-effective manufacturing, strong API capabilities, and global pharmaceutical companies seeking alternatives to Chinese supply chains. Emerging drug modalities like Cell and Gene Therapy are accelerating this transformation, with Asian CDMOs becoming key players in innovative pharmaceutical solutions. The broader APAC healthcare sector is also witnessing remarkable expansion, projected to contribute 40% to global healthcare growth by 2030.

"Indian pharma services are priced 20% lower than Chinese counterparts" - BCG Report
New Delhi, February 9: India's Contract Development and Manufacturing Organization (CDMO) market is poised for exponential growth, expected to expand from USD 7 billion to USD 14 billion by 2028, capturing 4-5 per cent of the global market, according to BCG report.

Key Points

1

India poised to capture 4-5% of global CDMO market

2

Emerging drug modalities driving pharmaceutical innovation

3

APAC healthcare market projected to reach $5 trillion by 2030

This surge is driven by India's strong position in Active Pharmaceutical ingredients (API) and generic drug manufacturing, along with cost advantages over China.

Some Indian CDMOs have witnessed a 50 per cent year-on-year increase in Requests for Proposals (RFPs) in 2024, as global pharmaceutical companies look to diversify supply chains beyond China. Indian pharma services are priced 20 per cent lower than their Chinese counterparts, making them a competitive alternative.

The biopharmaceutical sector is experiencing a shift towards innovative drug modalities that are expected to outpace traditional small-molecule drugs in the coming decade.

Key emerging modalities include Cell and Gene Therapy, projected to grow at 45 per cent CAGR, Antibody-Drug Conjugates (ADCs), expected to expand at 25 per cent CAGR, and Nucleic Acid Therapeutics, forecasted to grow at 36 per cent CAGR.

With the global CDMO market for new drug modalities expected to reach USD 20 billion by 2028, Asian CDMOs are emerging as key players, offering scalable, cost-effective solutions for global pharmaceutical companies.

The broader Asia-Pacific (APAC) healthcare sector is witnessing rapid transformation, with Foreign Direct Investment (FDI) in healthcare doubling since 2008.

The APAC healthcare market is projected to reach USD 5 trillion by 2030, contributing 40 per cent to global healthcare growth. This expansion is being fueled by rising income levels.

The number of high-income households (earning USD 30,000+ annually) in Asia is set to grow fivefold, from 34 million in 2000 to 175 million by 2030.

Trade between India and the US is expected to increase by USD 102 billion between 2022 and 2033, while US-China trade will decline.

India and the broader APAC region are expected to see significant growth across multiple healthcare sectors. Pharmaceuticals are projected to grow at 9 per cent CAGR over the next five years, while MedTech is expected to expand at 8 per cent CAGR.

Digital Health is witnessing a 9 per cent CAGR, and Diagnostic Services are forecasted to grow at 6 per cent CAGR.

Leave a Comment

Your email won't be published

Tags:
CDMO Market Indian Pharmaceuticals Healthcare Innovation BCG Report Pharmaceutical Manufacturing
You May Like!